Why Farbe Firma is the Top Manufacturer of Iron Sucrose Injection
- Maulik Sudani
- 7 hours ago
- 7 min read
Last Updated: May 30, 2026
TL;DR: Iron Sucrose Injection — a sterile parenteral solution of the iron(III)-hydroxide sucrose colloidal complex, supplied most commonly as 20 mg elemental iron per mL in 2.5 mL (50 mg), 5 mL (100 mg) and 10 mL (200 mg) ampoules and vials — is the intravenous iron replacement of choice for iron-deficiency anaemia in patients who cannot tolerate or do not respond to oral iron, above all in chronic kidney disease and haemodialysis, but also in inflammatory bowel disease, heavy uterine bleeding, the post-partum period, oncology and pre-operative anaemia optimisation. As a non-biological complex drug (a nanomedicine-class iron-carbohydrate colloid), its therapeutic safety depends on a tightly controlled molecular-weight distribution and minimal labile (free) iron so that iron is delivered to transferrin and ferritin rather than released into the plasma. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Iron Sucrose Injection at our Gujarat, India facility and supplies it to nephrology and dialysis services, hospital tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Parenteral iron replacement (iron(III)-hydroxide sucrose colloidal complex) — Iron Sucrose Injection is the intravenous iron of choice for iron-deficiency anaemia when oral iron fails or is not tolerated, especially in chronic kidney disease and haemodialysis, and in IBD, post-partum anaemia, oncology and pre-surgical optimisation.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule and vial filling lines, dedicated handling for a colloidal iron-carbohydrate nanocomplex whose molecular-weight distribution and labile-iron content must be controlled batch to batch, with validated terminal sterilisation and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files, complex-characterisation data (GPC/SEC molecular-weight profile, labile-iron and total-iron assay) and CEP-style documentation for registrations including ministry-of-health, nephrology and dialysis-programme tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule and vial packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Iron Sucrose Injection Demands a Premium Manufacturer
Iron Sucrose Injection occupies a central role on the nephrology and anaemia-management shelf. It is the intravenous iron that dialysis units run week in and week out, because patients on haemodialysis lose iron continuously and cannot replace it with oral tablets against a background of inflammation and poor gut absorption. It is the agent that gastroenterologists use to correct the iron-deficiency anaemia of inflammatory bowel disease without aggravating the gut, that obstetricians use for severe post-partum anaemia, and that pre-operative anaemia clinics use to lift haemoglobin before major surgery and reduce transfusion. In each of these settings iron sucrose is given as a slow intravenous injection or short infusion, typically 100–200 mg per session, and the patient depends on the iron being delivered safely into the body's transport and storage proteins.
That clinical reality places real demands on the manufacturer. Iron sucrose is not a simple small molecule — it is a colloidal complex of a polynuclear iron(III)-oxyhydroxide core surrounded by a sucrose shell, a so-called non-biological complex drug whose behaviour in the body is governed by its particle size, its molecular-weight distribution and the amount of weakly bound, labile iron it carries. If the complex is too weak or carries too much free iron, that iron can saturate transferrin and appear in the plasma, driving oxidative stress and hypotensive or hypersensitivity reactions; if it is too tightly bound, iron utilisation falls. Reproducing the reference complex batch after batch — same core size, same molecular-weight profile, same low labile-iron fraction — is a formulation and process-control discipline, not a simple fill-finish job. Choosing an Iron Sucrose Injection manufacturer that treats complex characterisation, labile-iron control, particle-size reproducibility and container-closure integrity as core engineering disciplines is what protects dialysis and anaemia patients at the bedside.
What Sets a World-Class Iron Sucrose Injection Manufacturer Apart
A world-class manufacturer of Iron Sucrose Injection invests in three areas that weaker suppliers underfund: reproducible synthesis and characterisation of the iron(III)-hydroxide sucrose colloid so that every batch matches the reference molecular-weight distribution, rigorous control of labile (weakly bound) iron so that free iron is not released on injection, and tender-ready dossier support for a product procured almost entirely through nephrology, dialysis and ministry-of-health channels. It starts with the active complex — manufactured or sourced to a defined polynuclear-core size and sucrose-to-iron ratio, with total-iron assay, labile-iron limits, pH and molecular-weight profile cross-checked before release.
Formulation, filling and packaging then have to preserve the colloid end to end. The bulk solution is held at the controlled alkaline pH (around 10.5–11.1) at which the complex is stable, adjusted for total iron at 20 mg/mL, sterile-filtered and filled under ISO Class 5 air into clear-glass ampoules or vials, then terminally sterilised on validated cycles that have been shown not to degrade the complex. In-process and release testing confirm total iron content, the labile-iron fraction within specification, the molecular-weight distribution by GPC/SEC, and the characteristic dark-brown colour and freedom from sediment. Container-closure integrity is verified on every batch, and stability is tracked under ICH Q1A long-term and accelerated conditions and ICH Q1B photostability protocols.
Quality Systems Behind Every Iron Sucrose Injection
Every Farbe Firma Iron Sucrose Injection batch is released only after a full stack of quality checks: total-iron assay against USP, BP, IP or EP reference standards, labile-iron determination within tight limits, molecular-weight distribution by gel-permeation/size-exclusion chromatography (GPC/SEC), pH, osmolarity, colour and absence of sediment, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification for the 2.5 mL, 5 mL and 10 mL formats at 20 mg iron/mL. Certificates of analysis are issued with full traceability back to the complex lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping qualified specifically not to shift the complex's molecular-weight profile, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because iron sucrose is a non-biological complex drug, we treat the molecular-weight profile and labile-iron fraction as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Iron Sucrose Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across haematinic, nephrology, anaesthesia, anti-infective, obstetric, neonatal and supportive-care categories. For Iron Sucrose Injection specifically, we supply 20 mg iron/mL solution in 2.5 mL (50 mg), 5 mL (100 mg) and 10 mL (200 mg) ampoules and vials under WHO-GMP conditions, with country-specific formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the complex-characterisation and labile-iron data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital and dialysis-unit supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, GPC/SEC molecular-weight and labile-iron characterisation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Iron Sucrose Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, characterisation data, artwork, production slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through complex synthesis and characterisation, labile-iron control, molecular-weight profiling, terminal-sterilisation qualification, container-closure and stability choices in real detail. For an intravenous iron given repeatedly to dialysis and anaemia patients, where complex quality directly governs safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Iron Sucrose Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Iron Sucrose Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles qualified not to shift the complex profile, and continuous environmental monitoring.
Which strengths and pack sizes of Iron Sucrose Injection do you supply?
Our standard presentation is 20 mg elemental iron per mL in 2.5 mL (50 mg), 5 mL (100 mg) and 10 mL (200 mg) clear-glass ampoules and vials. Custom fill volumes and country-specific pack configurations are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations and complex characterisation for Iron Sucrose Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, complex-characterisation data including GPC/SEC molecular-weight distribution and labile-iron limits, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets.
How does Farbe Firma assure the quality and safety of Iron Sucrose Injection?
We hold the complex at its stable alkaline pH, control total iron at 20 mg/mL, keep the labile-iron fraction within tight limits, verify the molecular-weight distribution by GPC/SEC on every batch, qualify the terminal sterilisation cycle specifically not to shift the complex profile, run particulate, endotoxin and sterility testing, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Iron Sucrose Injection contract manufacturing?
MOQs vary by fill volume, ampoule or vial format, label complexity and dossier requirements. For the 50 mg, 100 mg and 200 mg presentations we accommodate dialysis-unit, hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments